Physician profile
Jeny Thomas
NPI 1982166997
$1,043.63
in general payments reported to CMS, 2019-2025
18 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $344 · 2023: $484 · 2024: $18.59 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $699.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $189.06 | 2022-2025 | Verquvo, Belsomra, Steglatro |
| Lilly USA, LLC | $107.35 | 2022-2023 | Mounjaro |
| Novo Nordisk INC | $104.51 | 2022-2023 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $85.94 | 2023-2025 | Benlysta, Trelegy Ellipta |
| Abbvie INC. | $78.34 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.85 | 2022 | |
| Ucb, INC. | $65.34 | 2022-2025 | Bimzelx |
| Astrazeneca Pharmaceuticals LP | $48.10 | 2022-2025 | Farxiga, Airsupra |
| Xeris Pharmaceuticals, INC. | $45.74 | 2022-2023 | Gvoke Hypopen |
| Abbott Laboratories | $42.63 | 2023-2025 | Freestyle Libre 3 |
| Medtronic, INC. | $39.14 | 2023 | Corevalve Evolut R |
| Astellas Pharma US INC | $34.49 | 2022-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $28.95 | 2022-2023 | |
| Exact Sciences Corporation | $24.90 | 2023 | Cologuard Collection Kit |
| Lifescan, INC. | $22.79 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.39 | 2023 | |
| Scilex Pharmaceuticals INC. | $19.85 | 2022 | |
| Amgen INC. | $13.26 | 2023 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeny Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.